Anticoagulants are the cornerstone for prevention and treatment of thrombosis but are not
completely effective, and concerns about the risk of bleeding continue to limit their uptake …

Chronic kidney disease is present in almost 10% of the world population and is associated
with excess mortality and morbidity. Reduced glomerular filtration rate and the presence and …

Introduction Venous thromboembolism (VTE) is a leading cause of cardiovascular morbidity
and mortality. The majority of VTE events are hospital‐associated. In 2008, the …

Background Glioblastoma patients are considered to be at high risk of venous
thromboembolism (VTE) and major bleeding (MB), although reliable incidence estimates are …

Chronic kidney disease (CKD) is being diagnosed increasingly worldwide. It is often
identified in individuals with co-morbidities, which may increase the already heightened risk …

Anticoagulation is the mainstay of stroke prevention in appropriate patients with atrial
fibrillation. Due to advances in pharmacotherapy the anticoagulants used for this purpose …

Metformin, the most frequently prescribed medicine for the management of type 2 diabetes,
has been shown to reduce cardiovascular events in diabetic patients in pre-clinical and …

Strategies to prevent thrombosis in antiphospholipid antibody (aPL)–positive patients are of
the utmost importance. The risk of thrombosis in patients with aPLs varies, depending on …

These days, anticoagulants are in great demand. They are used as a prophylaxis for
thromboembolic complications in various diseases and conditions in general therapeutic …

Антикоагулянты-крайне востребованные препараты в наши дни. Они используются в
качестве профилактики тромбоэмболических осложнений при различных …